NDA 050621 · Lederle
Suprax
Cefixime · Oral
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Mar 13, 2009 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1989
Apr 28, 1989
Approved uses
7
Original approval plus efficacy supplements
Registered trials
46
6 Phase 3, 6 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 13, 2009 Supplement 4 · Efficacy
- Mar 13, 2009 Supplement 16 · Efficacy
- Mar 13, 2009 Supplement 14 · Efficacy
- Mar 13, 2009 Supplement 20 · Efficacy
- Mar 13, 2009 Supplement 15 · Efficacy
- Feb 5, 1993 Supplement 10 · Efficacy
- Apr 28, 1989 Original approval · Type 1 - New Molecular Entity
2 products under this application
- SUPRAX · CEFIXIME 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- SUPRAX · CEFIXIME 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Cefixime" as an intervention, any sponsor and status, largest first.
- Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSMPivotal-lookingActive, not recruiting
University of WashingtonAcademic, hospital or other
NCT06468462 · 2,900 participants (planned) · Start Oct 29, 2025 · Primary completion Oct 31, 2028
Drug: WHO-recommended periodic presumptive treatment; Doxycycline post-exposure prophylaxis · For: Gonorrhea Male; Chlamydia (Male); Syphilis Male
Sites: Kisumu, Kenya; Mombasa, Kenya; Nairobi, Kenya
- The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)Pivotal-lookingCompleted
Oxford University Clinical Research Unit, VietnamAcademic, hospital or other
NCT04349826 · 2,150 participants · Start May 23, 2021 · Primary completion Dec 31, 2025
Drug: Azithromycin; Cefixime and 1 more · For: Typhoid Fever
Sites: Lalitpur, Nepal
- The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT01595529 · 717 participants · Start May 18, 2012 · Primary completion Jun 30, 2019
Drug: Cefixime; Cephalexin and 1 more · For: Urinary Tract Infection
Sites: Pittsburgh, Pennsylvania
- Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years OldPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT00136656 · 700 participants · Start Jul 2005 · Primary completion Jun 2008
Drug: antibiotic; antibiotics · For: Pyelonephritis
Sites: Bicêtre, France; Bordeaux, France; Boulogne, France · 12 sites in all
Tata Memorial HospitalGovernment (non-federal)
NCT02830230 · 508 participants (planned) · Start Jul 2016 · Primary completion Dec 2017
Drug: Tab cefixime,Tab Azithromycin · For: Cervical Inflammation and Human Papilloma Virus Performance
Sites: Mumbai, India
- 3-day IV Antibiotic Treatment Versus 3-day IV Followed by 7-day Oral Antibiotic Treatment for AP in ChildrenPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT05544565 · 480 participants (planned) · Start Mar 22, 2023 · Primary completion Jan 2028
Drug: IV Antibacterial Agents; Orally antibacterial agents · For: Pyelonephritis Acute
Sites: Corbeil-Essonnes, France; Orsay, France; Clamart, France · 15 sites in all
- Cefixime Clinical TrialPivotal-lookingRecruiting
University of Southern CaliforniaAcademic, hospital or other
NCT04958122 · 400 participants (planned) · Start Jun 20, 2021 · Primary completion Jan 1, 2027
Drug: Cefixime 400mg; benzathine penicillin · For: Syphilis; Human Immunodeficiency Virus
Sites: Los Angeles, California
- Optimizing the Diagnostic Approach to Cephalosporin Allergy TestingPivotal-lookingRecruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06406114 · 300 participants (planned) · Start May 5, 2025 · Primary completion Jul 1, 2028
Drug: Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing; Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge and 3 more · For: Drug Allergy; Cephalosporin Allergy; Drug Hypersensitivity and 4 more
Sites: Scottsdale, Arizona; San Francisco, California; Boston, Massachusetts · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Clinical pharmacokinetics of cefixime: a systematic review.
Ajmal M, Zamir A, Rehman AU, et al. · Xenobiotica 2023 · Systematic Review
- Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Kuehn R, Stoesser N, Eyre D, et al. · Cochrane Database Syst Rev 2022 · Research Support, Non-U.S. Gov't, Systematic Review
- Antibiotics for gonorrhoea in pregnancy.
Brocklehurst P · Cochrane Database Syst Rev 2002 · Systematic Review
- Safety profile of cefixime.
Tally FP, Desjardins RE, McCarthy EF, et al. · Pediatr Infect Dis J 1987 · Clinical Trial
- [Modern pharmacotherapy of acute bacterial sinusitis: results of an open randomized clinical trial of the therapeutic equivalence of Cefixime EXPRESS and Suprax Solutab].
Kryukov AI, Gurov AV, Shadrin GB, et al. · Vestn Otorinolaringol 2024 · Randomized Controlled Trial, Comparative Study
- Effectiveness of Cefixime for the Treatment of Neisseria gonorrhoeae Infection at 3 Anatomic Sites: A Systematic Review and Meta-Analysis.
Yang KJ, Kojima N, Bristow CC, et al. · Sex Transm Dis 2023 · Meta-Analysis, Systematic Review
Sponsor: Lederle
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.